NCT06468774Recruiting
Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome
Source: ClinicalTrials.gov · Last updated 30 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 12 Jun 2024
- Start date
- 10 Jun 2024
- Primary completion date
- 31 May 2037
- Lead sponsor
- Oslo University Hospital
- Diseases
- Crohn's disease
- NCT number
- NCT06468774
What you commit to
- Study type: Observational
- Planned participants: 180
- From 10 Jun 2024 to the primary completion date, 31 May 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- For the patient groups :
- Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.
- Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.
- For the control group:
- Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy.
- Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound.
- Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of vascular surgery, Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.